Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | MAX | P61244 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21937090 | 0.84 | LMNA (0.48) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL19805274 | 0.82 | MYC (0.45) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL19805279 | 0.82 | MYC (0.45) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL19805275 | 0.81 | MYC (0.44) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL19805270 | 0.80 | MYC (0.44) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL19805271 | 0.79 | MYC (0.43) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL20429711 | 0.78 | LMNA (0.52) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL15685312 | 0.78 | LMNA (0.52) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL3891762 | 0.78 | LMNA (0.52) | MYCMAXMEN1KMT2ALMNA | |
| SCHEMBL15240354 | 0.78 | LMNA (0.52) | MYCMAXMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | MME, ACE, REN | MYC 1680/4885MAX 409/4885MEN1 1768/4885 |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | MME, ACE, REN | MYC 1680/4885MAX 409/4885MEN1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.